Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07284472 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy of EXV-802 and EXV-801 in the Treatment of Agitation in Alzheimer's Disease Dementia
A Phase 2 study of Agitation Associated With Alzheimer's Disease Dementia, sponsored by Exciva.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 300
- Enrollment target
- 13
- Study locations
NCT07284472 is a Phase 2 study of Agitation Associated With Alzheimer's Disease Dementia that is actively recruiting participants, run by Exciva. The registered enrollment target is 300 participants. The trial reports 13 study locations across 9 states.
The verdict
NCT07284472, a Phase 2 study of Agitation Associated With Alzheimer's Disease Dementia, is actively recruiting participants, sponsored by Exciva.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 300 participants
- Enrollment target
- 13
- Study locations
Study Summary
The goal of this clinical trial is to evaluate the safety and efficacy of EXV-802 and EXV-801 in treatment of agitation in participants with Alzheimer's Disease dementia.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG EXV-802
- DRUG EXV-801
Study Locations (13)
Ontario
- Sunnybrook Health Sciences Centre - North York
- Baycrest Centre for Geriatric Care - North York
- Kawartha Centre - Peterborough
- Ontario Shores Centre for Mental Health Sciences - Whitby
New York
- Integrative Clinical Trials - Brooklyn
- Manhattan Behavioral Medicine - New York
California
- Esperanza Clinical - Murrieta
Indiana
- Josephson Wallack Munshower Neurology PC - Indianapolis
Mississippi
- Precise Research Centers - Flowood
Ohio
- Insight Clinical Trials - Independence
Oregon
- Oregon Health & Science University - Portland
Vermont
- The Memory Clinic - Bennington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2026-02-02 |
| Est. Completion | 2029-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07284472
The ClinicalTrials.gov registry entry for NCT07284472 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 300 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Exciva, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Agitation Associated With Alzheimer's Disease Dementia appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT07284472 reports 13 study locations spanning 9 distinct geographic areas - top geographies include Ontario, New York, California.
Frequently Asked Questions
What is clinical trial NCT07284472 about?
NCT07284472 is a clinical study titled "Safety and Efficacy of EXV-802 and EXV-801 in the Treatment of Agitation in Alzheimer's Disease Dementia". The goal of this clinical trial is to evaluate the safety and efficacy of EXV-802 and EXV-801 in treatment of agitation in participants with Alzheimer's Disease dementia.
What is the current status of trial NCT07284472?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 300 participants. The study started on 2026-02-02. Estimated completion is 2029-02.
What conditions does trial NCT07284472 study?
This clinical trial studies the following conditions: Agitation Associated With Alzheimer's Disease Dementia.
What interventions are being tested in trial NCT07284472?
The interventions under investigation include: Placebo (DRUG), EXV-802 (DRUG), EXV-801 (DRUG).
Who is sponsoring clinical trial NCT07284472?
This trial is sponsored by Exciva, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07284472 being conducted?
This trial has 13 study locations across California, Indiana, Mississippi, New York, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.